|
| | HR0450HAM001 | | LRB097 12219 RPM 58995 a |
|
|
1 | | AMENDMENT TO HOUSE RESOLUTION 450
|
2 | | AMENDMENT NO. ___. Amend House Resolution 450 by replacing |
3 | | everything after the title with the following: |
4 | | "WHEREAS, In response to increasing prescription drug |
5 | | costs, many employer health plans and employer prescription |
6 | | drug plans have increased enrollee cost-sharing amounts, |
7 | | instituted coinsurance, and created specialty tiers; and
|
8 | | WHEREAS, The increase in price of specialty prescription |
9 | | drugs of 19.6% in 2010 versus a 1.4% increase for traditional |
10 | | drugs and the expected increase of specialty drugs of an |
11 | | additional 27.5% by 2013 creates significant financial |
12 | | pressures on employer health plans, employer prescription drug |
13 | | plans, and individuals who purchase an individual health |
14 | | insurance policy; and |
15 | | WHEREAS, The National Conference of State Legislatures |
|
| | HR0450HAM001 | - 2 - | LRB097 12219 RPM 58995 a |
|
|
1 | | reports that between the years 2000 and 2009, copayments for |
2 | | insured workers have increased for specialty-tier drugs; and
|
3 | | WHEREAS, Medicare has used specialty tiers since 2006 to |
4 | | help control prescription drug costs on behalf of taxpayers; |
5 | | and |
6 | | WHEREAS, Nationally 11% of employers utilize a coinsurance |
7 | | or percentage of the cost of fourth-tier or specialty-tier |
8 | | prescription medications to help control the cost of their |
9 | | prescription drug benefit plans; and |
10 | | WHEREAS, Fourth-tier or specialty-tier medications often |
11 | | include medications for chronic diseases, including certain |
12 | | types of cancer, hemophilia, multiple sclerosis, myositis, |
13 | | neuropathy, arthritis, human immunodeficiency virus, and other |
14 | | diseases and disorders; and
|
15 | | WHEREAS, Specialty-tier benefits and step therapy are |
16 | | strategies offered by employer health plans and employer |
17 | | prescription drug plans to incentivize plan participants to |
18 | | utilize lower cost generics or preferred brand alternatives; |
19 | | and |
20 | | WHEREAS, Coinsurance, cost-sharing, and specialty-tier |
21 | | pricing place significant and onerous financial burdens upon |
|
| | HR0450HAM001 | - 3 - | LRB097 12219 RPM 58995 a |
|
|
1 | | insured individuals with chronic health care issues requiring |
2 | | prescription medication, in many cases leading to decreased |
3 | | adherence or failure to take medications as prescribed, |
4 | | resulting in acute incidents and negative health outcomes; |
5 | | therefore, be it
|
6 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE |
7 | | NINETY-SEVENTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that |
8 | | the Department of Insurance is requested to study the cost of |
9 | | specialty drugs and the availability and accessibility of |
10 | | manufacturer discounts and assistance plans to individuals and |
11 | | employers; and be it further |
12 | | RESOLVED, That the study shall (1) determine the impacts |
13 | | of cost sharing, coinsurance, and specialty-tier pricing for |
14 | | prescription medications on individuals and employer health |
15 | | plans; (2) determine the percentage of small employers in |
16 | | Illinois providing prescription drug benefits and the impact of |
17 | | the high cost of specialty drugs on the ability of small |
18 | | employers and individuals to continue such prescription drug |
19 | | benefits; (3) identify and evaluate options for reducing the |
20 | | cost of specialty drugs on individuals and small employers; and |
21 | | be it further |
22 | | RESOLVED, That the Department of Insurance shall report to |
23 | | the General Assembly on the first day of the regular session, |